Hi, what are you looking for?
By Mary de Wet
PolyPid said Tuesday that it has produced three process-validation batches of D-PLEX, its lead drug candidate to prevent surgical-site infections, putting the company on track to seek regulatory approval.
The Israel-based biopharma company didn’t give a timeline for when it would submit new drug and marketing authorization applications…
Read the full article here
Follow Play Earnings CallPlay Earnings Call Disc Medicine, Inc. (IRON) Discusses ASH Conference Data Updates and Portfolio Progress Including Anemia and Iron Restriction Programs...
This article was written by Follow I am a stock analyst with over 20 years of experience in quantitative research, financial modeling, and risk...
Watch full video on YouTube
